The X-ray repair cross-complementing group 3 (XRCC3) is a highly suspected candidate gene for cancer susceptibility. However, association studies on the XRCC3 polymorphisms (4541A4G, Thr 241 Met, 17893A4G) in cancer have shown conflicting results. Therefore, we performed a meta-analysis to better assess the purported associations. Forty eight eligible case-control studies including 24 975 cancer patients and 34 209 controls were selected for our meta-analysis. Overall, individuals carrying the XRCC3 Met/Met genotype showed a small cancer risk under a recessive genetic model. The subgroup and metaregression analysis demonstrated different scenarios concerning the XRCC3 Met/Met genotype's role in cancer susceptibility for different subgroups. Specially, there was a significantly increased risk of breast cancer (OR, 1.14; P ¼ 0.0004; 95% CI, 1.06 -1.23; P ¼ 0.37 for heterogeneity), elevated but not significant risk of cancer for head and neck, bladder, surprisingly, a significantly decreased risk of non-melanoma skin cancer (OR, 0.76; P ¼ 0.007; 95% CI, 0.62-0.93; P ¼ 0.61 for heterogeneity). A significantly elevated risk of cancer was observed in population-based case-control studies but not in nested or hospital based studies. Similarly, we found a significantly increased risk of cancer for A4541G and a decreased risk for A17893G under dominant genetic models. Our meta-analysis results support that the XRCC3 might represent a lowpenetrance susceptible gene especially for cancer of breast, bladder, head and neck, and non-melanoma skin cancer. A single larger study should be required to further evaluate gene -gene and geneenvironment interactions on XRCC3 polymorphisms and tissue-specific cancer risk in an ethnicity specific population.
Introduction
There is growing evidence that human cancer can be initiated by DNA damage caused by UV, ionizing radiation, and environmental chemical agents. Linkage analysis in multigenerational families affected with cancer has led to the identification of high penetrant cancer genes with roles in the repair of damaged DNA, such as ATM, ERCC2, BRCA1, BRCA2, etc. However, the individual high-risk alleles are generally rare and are estimated to account for only B5% of the incidence of cancer in the population, so several to many other low-penetrant genes have been considered to be involved in the pathogenesis of cancer, each contributing a small effect to the total genetic component. 1 The X-ray repair cross-complementing group 3 (XRCC3), one of the DNA repair genes, codes for a protein participating in homologous recombination repair (HRR) of DNA double-strand breaks (DSB). It is a member of an emerging family of Rad-51-related proteins that may take part in homologous recombination to repair DSB and maintain genome integrity.
2 XRCC3-deficient cells exhibited defects in Rad51 focus formation after radiation damage and demonstrated genetic instability and increased sensitivity to DNA damaging agents. 3 Carriers of the variant allele of XRCC3 Thr 241 Met had relatively high DNA adduct levels in lymphocyte DNA, indicating that this polymorphism was associated with relatively low DNA repair capacity. 4 Therefore, XRCC3 has been of considerable interest as a candidate susceptibility gene for cancer.
A large number of molecular epidemiologic studies have been preformed to evaluate the role of XRCC3 polymorphisms on various neoplasm, such as cancer of breast, lung, bladder, head and neck, skin, etc. 5 -61 The Thr 241 Met substitution is the most thoroughly investigated polymorphism in XRCC3 due to a (C-4T) transition at exon7 (XRCC3-18067C4T, rs861539). Another two polymorphisms investigated by a few studies is XRCC3-4541A4G (5 0 -UTR, rs1799794) and XRCC3-17893A4G (IVS6-14, rs1799796). However, the results remain fairly conflicting rather than conclusive. One factor that would contribute to the discrepancy between different studies is that these polymorphisms might play a different role in different tumor sites. Also, even at the same tumor site, considering the possible small effect size of these genetic polymorphisms to cancer and the relatively small sample size in some studies, the discrepancy will become apparent since some single studies may have been underpowered to detect a small but real association.
Given the amount of accumulated data now available, it is important to perform a quantitative synthesis of the evidence using rigorous methods. The aim of this study was to assess the association of XRCC3 polymorphisms with the risk of cancer by conducting a meta-analysis from all eligible case -control studies published to date. Our results suggest that XRCC3 would not be a major risk factor for cancer but might represent a low-penetrance susceptible gene in cancer susceptibility.
Methods

Identification and eligibility of relevant studies
To identify all studies that examined the association of XRCC3 polymorphisms with cancer, we conducted a computerized literature search of PubMed database (from January 1991 to April 2006) using the following keywords and subject terms: 'X-ray repair cross-complementing group 3', 'XRCC3', 'polymorphism', 'polymorphisms', and 'cancer'. References of retrieved articles were also screened. When a study reported results on different racial descent subpopulations or tumor sites, we treated each subpopulation or tumor as a separate comparison in our meta-analysis.
Studies included in the current meta-analysis have to meet all the following criteria: (1) use an unrelated casecontrol design, (2) have available genotype frequency, and (3) genotype distribution of control population must be in Hardy -Weinberg equilibrium (HWE).
Data extraction
Two investigators independently extracted the data and reached a consensus on all items. Data were collected on the authors, journal, years of publication, country of origin, demographics, selection and characteristics of cancer cases and controls, matched factors as well as adjusted factors, XRCC3 polymorphisms genotyping information, interactions between environmental factors and genes, and racial descent (categorized as Asian, European, or mixed descent).
Statistical analysis
The strength of the association between XRCC3 polymorphisms and cancer was measured by odds ratio (OR), which was calculated according to the method of Woolf. 62 We calculated the combined OR under dominant, recessive or additive genetic model for each polymorphism, respectively. A w 2 -based Q statistic test was performed to assess the between-study heterogeneity. 63 Owing to the low power of the statistic, heterogeneity was considered significant for Po0. 10 . A fixed effects model using the Mantel -Haenszel method or a random-effects model using the DerSimonian and Laird method were used to pool the results. 64 The significance of the pooled OR was determined by the Z-test. For Thr 241 Met, subgroup analysis was performed stratified by the study character of racial descent, study design and tumor site, respectively (If the tumor site contains less than three independent individual studies, it was categorized into the 'other sites' group.). Furthermore, the factors of racial descent, study design and tumor site were examined in a meta-regression model to explore the possible heterogeneity between different kinds of studies. A randomeffects weighted linear regression model was used, whereby the study-specific log (OR) was regressed on the characters of each study. 65 The regression incorporated both the within-study variance as well as the between-study variance, and the weights were estimated using restricted maximum likelihood. Statistical significance was defined as a P-value less than 0.10 because of the relatively weak statistical power. Publication bias was investigated by using a funnel plot, in which the standard error of log (OR) of each study was plotted against its OR. Funnel plot asymmetry was further assessed by the method of Egger's linear regression test. 66 Hardy -Weinberg equilibrium was tested by the w 2 -test for goodness of fit or Fisher's exact probability test, where appropriate.
Analyses were performed using the software Stata version 7, ReviewManage 4.2 (Oxford, England, UK). All P-values were two-sided.
Results
Study inclusion
Through literature search and selection based on the inclusion criteria, 57 studies (69 comparisons) were found, but only 48 studies (57 comparisons) met our inclusion criteria, as listed in Table 1 
Meta-analysis database
We established a database according to the extracted information from each article. Table 1 lists the tumor site of the study, ethnicity of the population, study design, the genotype frequency of cases and controls, and the rare variant allele frequency in controls for each XRCC3 polymorphisms. Overall, the quality of these included studies was good: methods of recruitment, total numbers, characters of participants and inclusion criteria were generally clearly stated; Tumors were all confirmed by histological or pathogenic analysis; most studies (74%) matched in age, sex, and ethnicity in frequency. A classic PCR-RFLP assay was performed in 50% of the studies, 58% randomly repeated a portion of samples while genotyping. However, only 25% of the studies described use of blindness of the case -control status of DNA samples while genotyping; not more than half of the studies (33%) investigated the interactions between XRCC3 polymorphisms and environmental factors or other genes; few studies have been done to explore the role of XRCC3 haplotype on cancer susceptibility (12%). Met/Met showed a small cancer risk compared with the individuals with the (Thr/Thr þ Thr/Met) genotype. However, the subgroup and meta-regression analysis demonstrated different scenarios concerning the role of Met 241 allele in cancer susceptibility for different subgroups. We identified two potential sources of between-study heterogeneity: tumor site and study design. Similarly, we found a significantly increased risk of cancer for XRCC3 A4541G and a decreased risk for A17893G under dominant genetic models. However, considering the limited studies of the A4541G and A17893G polymorphisms, our results related to these two polymorphisms should always be treated as preliminary. In addition, we evaluated the linkage disequilibrium (LD) patterns among the three polymorphisms using the Hapmap data (EGP_SNPS-PDR90, CEU, HCB) and found that these polymorphisms are in tight LD, so associations found with one of these polymorphisms might be the result of LD with one of the other two polymorphisms. Nevertheless, our analysis suggested that XRCC3 may play a small role in cancer susceptibility, which is consistent with the characteristics of lowpenetrance genes. Both biological and biochemical evidence indicate a direct role for XRCC3 in DSBs repair. 67, 68 Functional data also suggested that the XRCC3 Thr 241 Met polymorphism may be associated with slightly but not significantly decreased DNA repair capacity. 69 Therefore, it seems much reasonable to take polymorphisms in XRCC3 as the low-penetrance variant candidate for cancer susceptibility.
As the first report, Winsey et al 44 found that the Met 241 allele was significantly associated with increased risk of melanoma in the UK. Subsequently, Matullo et al 37 replicated this positive association in bladder cancer in an Italian population. Thereafter, more and more studies were conducted in order to further verify this purported association in different tumor sites across different nations. However, the results were fairly confusing rather than conclusive. Most studies cannot confirm a significantly The P-value of meta-regression coefficient.
XRCC3 polymorphisms and cancer risk S Han et al increased risk in cancer of the polymorphisms, and even, some studies documented a significant protective effect on cancer susceptibility. Actually, it should be not uncommon for the same polymorphism playing a different role in cancer susceptibility across different populations since cancer is a complex disease. Our meta-analysis results revealed some reasons that might contribute to the inconsistent result across different studies. First, cancer is a complex disease and genetic heterogeneity exists in different tumor sites. The XRCC3 Thr 241 Met polymorphism might be an increased risk factor for cancer of breast, head and neck, bladder but not for lung, leukemia, colorectal, gastric and melanoma skin cancer, and even a decreased risk factor for non-melanoma skin cancer. Our incomplete understanding of the biological function of the allele makes it difficult to further interpret potentially meaningful differences that may be tissue specific. Second, study design of prospective or retrospective study might make some differences between different studies (larger effects in populationbased case -control studies compared with cohort studies, P ¼ 0.009). Third, different genetic background may also contribute to the discrepancy. There were significant differences in terms of the variant Similarly, very few studies investigated the gene -gene interactions or pathway analysis which would provide more comprehensive insight into the studied associations and should be considered in future genetic epidemiological studies.
As being often the case with meta-analysis, several factors limited the current study. First, the effect of XRCC3 is perhaps best represented by its haplotype. However, most studies included in the meta-analysis restricted their analysis to Thr 241 Met polymorphism of XRCC3 only and few did the XRCC3 haplotypic analysis on cancer susceptibility. It was difficult to study the role of a particular haplotype on cancer susceptibility in current meta-analysis. Second, although we attempted to evaluate the environmental modification effects such as smoking, alcohol, and food etc, only a few investigators reported the same environmental condition and the definition of each stratum varied among studies. Third, multiple testing problem is an inevitably threat for our meta-analysis. In the current analysis, a large number of comparisons have been considered since we analyzed the different cancer types, with three different polymorphisms, under three different genetic models. Finally, the study numbers included in the subgroup meta-analysis was small. Therefore, some subgroup analysis may not have enough statistical power to explore the association of these polymorphisms with cancer susceptibility. In spite of this, our meta-analysis shares some key advantages in several aspects. First, substantial number of cases and controls were pooled from different studies, which significantly increased statistical power of the analysis. Second, the quality of case -control studies included in current meta-analysis was good and met our inclusion criterion. Third, we did not detect any publication bias indicating that the whole pooled result should be unbiased.
In conclusion, our meta-analysis supports that the XRCC3 could not be a major increased risk factor for cancer but it might represent a low-penetrance susceptible gene especially for cancer of breast, bladder, head and neck, and non-melanoma skin cancer. A single larger study should be required to further evaluate gene -gene and gene -environment interactions on XRCC3 polymorphisms and tissue-specific cancer risk in an ethnicity specific population.
